211 related articles for article (PubMed ID: 26542126)
41. Involvement of glucocorticoid receptor activation on anti-inflammatory effect induced by peroxisome proliferator-activated receptor γ agonist in mice.
Yamamoto A; Kakuta H; Sugimoto Y
Int Immunopharmacol; 2014 Sep; 22(1):204-8. PubMed ID: 24975659
[TBL] [Abstract][Full Text] [Related]
42. Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor gamma in human skeletal muscle cells.
Chung SS; Kim M; Youn BS; Lee NS; Park JW; Lee IK; Lee YS; Kim JB; Cho YM; Lee HK; Park KS
Mol Cell Biol; 2009 Jan; 29(1):20-30. PubMed ID: 18936159
[TBL] [Abstract][Full Text] [Related]
43. The potential of antidiabetic thiazolidinediones for anticancer therapy.
Galli A; Mello T; Ceni E; Surrenti E; Surrenti C
Expert Opin Investig Drugs; 2006 Sep; 15(9):1039-49. PubMed ID: 16916271
[TBL] [Abstract][Full Text] [Related]
44. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.
Belvisi MG; Hele DJ; Birrell MA
Eur J Pharmacol; 2006 Mar; 533(1-3):101-9. PubMed ID: 16458290
[TBL] [Abstract][Full Text] [Related]
45. Metabonomic profiling revealed an alteration in purine nucleotide metabolism associated with cardiac hypertrophy in rats treated with thiazolidinediones.
Liu Y; Yan X; Mao G; Fang L; Zhao B; Liu Y; Tang H; Wang N
J Proteome Res; 2013 Dec; 12(12):5634-41. PubMed ID: 24164426
[TBL] [Abstract][Full Text] [Related]
46. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
Chetty VT; Sharma AM
Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
[TBL] [Abstract][Full Text] [Related]
47. [Role of PPARγ, a transcription factor in cardiovascular disease].
Mukohda M
Nihon Yakurigaku Zasshi; 2019; 154(2):56-60. PubMed ID: 31406043
[TBL] [Abstract][Full Text] [Related]
48. Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function.
Borchert M; Schöndorf T; Lübben G; Forst T; Pfützner A
Diabetes Technol Ther; 2007 Oct; 9(5):410-20. PubMed ID: 17931049
[TBL] [Abstract][Full Text] [Related]
49. PPARγ and chronic kidney disease.
Fogo AB
Pediatr Nephrol; 2011 Mar; 26(3):347-51. PubMed ID: 20676693
[TBL] [Abstract][Full Text] [Related]
50. Effects of thiazolidinediones on differentiation, proliferation, and apoptosis.
Chou FS; Wang PS; Kulp S; Pinzone JJ
Mol Cancer Res; 2007 Jun; 5(6):523-30. PubMed ID: 17579114
[TBL] [Abstract][Full Text] [Related]
51. Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer.
Inamoto T; Shah JB; Kamat AM
Urol Oncol; 2009; 27(6):585-91. PubMed ID: 19162510
[TBL] [Abstract][Full Text] [Related]
52. Thiazolidinediones promote axonal growth through the activation of the JNK pathway.
Quintanilla RA; Godoy JA; Alfaro I; Cabezas D; von Bernhardi R; Bronfman M; Inestrosa NC
PLoS One; 2013; 8(5):e65140. PubMed ID: 23741474
[TBL] [Abstract][Full Text] [Related]
53. PPARγ signaling and metabolism: the good, the bad and the future.
Ahmadian M; Suh JM; Hah N; Liddle C; Atkins AR; Downes M; Evans RM
Nat Med; 2013 May; 19(5):557-66. PubMed ID: 23652116
[TBL] [Abstract][Full Text] [Related]
54. [The role of PPARgamma agonists in kidney diseases].
Yokoyama Y; Doi S; Kawai T; Yorioka N
Nihon Rinsho; 2010 Feb; 68(2):317-22. PubMed ID: 20158103
[TBL] [Abstract][Full Text] [Related]
55. PPARgamma-independent antitumor effects of thiazolidinediones.
Wei S; Yang J; Lee SL; Kulp SK; Chen CS
Cancer Lett; 2009 Apr; 276(2):119-24. PubMed ID: 18790559
[TBL] [Abstract][Full Text] [Related]
56. Possible Protective Effects of Thiazolidinediones Antidiabetic Drugs in Colorectal Cancer.
Bahrambeigi S; Badalzadeh R; Shafiei-Irannejad V; Alizadeh A
Crit Rev Oncog; 2019; 24(3):251-258. PubMed ID: 32422023
[TBL] [Abstract][Full Text] [Related]
57. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?
Feinstein DL; Spagnolo A; Akar C; Weinberg G; Murphy P; Gavrilyuk V; Dello Russo C
Biochem Pharmacol; 2005 Jul; 70(2):177-88. PubMed ID: 15925327
[TBL] [Abstract][Full Text] [Related]
58. Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake.
Christensen KB; Minet A; Svenstrup H; Grevsen K; Zhang H; Schrader E; Rimbach G; Wein S; Wolffram S; Kristiansen K; Christensen LP
Phytother Res; 2009 Sep; 23(9):1316-25. PubMed ID: 19172665
[TBL] [Abstract][Full Text] [Related]
59. Angiotensin inhibition stimulates PPARgamma and the release of visfatin.
Storka A; Vojtassakova E; Mueller M; Kapiotis S; Haider DG; Jungbauer A; Wolzt M
Eur J Clin Invest; 2008 Nov; 38(11):820-6. PubMed ID: 19021699
[TBL] [Abstract][Full Text] [Related]
60. The nuclear hormone receptor PPARγ as a therapeutic target in major diseases.
Schmidt MV; Brüne B; von Knethen A
ScientificWorldJournal; 2010 Nov; 10():2181-97. PubMed ID: 21057731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
